Staff Profile

I joined the Health Economics Group at the Population Health Sciences Institute in 2020.

Qualifications:

MSc Economics & Health Economics (Distinction), 2019, University of Sheffield

BA Economics, 2018, University of Sheffield

My research focuses on decision analytic modelling for health technology assessments. I am currently working for the Technology Assessment Reviews (TARs) programme, focusing on evidence appraisal for the National Institute of Health and Care Excellence (NICE). I have additional experience building decision models for: economic evaluations along systematic reviews; economic evaluations alongside clinical trials; and economic evaluations for diagnostic interventions in prostate cancer. I am also part of the Evidence Assessment Group (EAG) at Newcastle University.

• Articles

  • Robinson T, Hill S, Orozco-Leal G, Kernohan A, King W, Oluboyede Y. Valuing selected WAItE health states using the Time Trade-Off methodology: findings from an online interviewer-assisted remote survey. Journal of Patient-Reported Outcomes 2024, 8(1).
  • Orozco Leal G, Johnson EE, Hosseinijebeli S, Robinson T, Homer T, Eastaugh C, Richmond C, Tanner L, Meader N, Kenny R, Wallace SA, Rice S. Considerations for the cure assumption in a NICE Single Technology Appraisal of nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small cell lung cancer: Evidence Assessment Group perspective. PharmacoEconomics 2024, 42, 133-136.
  • Beyer F, Rice S, Orozco-Leal G, Still M, O'Keefe H, O'Connor N, Stoniute A, Craig D, Pereira S, Carr L, Leeds J. Clinical and cost effectiveness of endoscopic bipolar radiofrequency ablation for the treatment of malignant biliary obstruction: a systematic review. Health Technology Assessment 2023, 27(7), 1-118.
  • Orozco leal G, Armstrong N, Kernohan A, Ahmadu C, Coughlan D, McDermott K, Duffy S, O'Meara S, Robinson T, Vale L, Kleijnen J. Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 2023, 41(7), 741-750.

• Conference Proceedings (inc. Abstracts)

  • Beyer F, Rice S, Orozco-Leal G, Still M, O'Keefe H, O'Connor N, Stoniute A, Craig D, Pereira S, Carr L, Leeds J. PTU-35 Endoscopic bipolar radiofrequency ablation for treating malignant biliary obstruction: Systematic review and meta-analysis. In: British Society of Gastroenterology (BSG) Annual Meeting. 2021, Online: BMJ Publishing Group.
  • Beyer F, Rice S, Orozco-Leal G, Still M, O'Keefe H, O'Connor N, Stoniute A, Craig D, Pereira S, Carr L, Leeds J. P-P21 Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by unresectable cancer: systematic review of clinical and cost effectiveness. In: UGI Congress 2021. 2021, Belfast: Oxford University Press.

• Review

  • Rice S, Carr K, Sobiesuo P, Shabaninejad H, Orozco-Leal G, Kontogiannis V, Marshall C, Pearson F, Moradi N, O'Connor N, Stoniute A, Richmond C, Craig D, Allegranzi B, Cassini A. Economic evaluations of interventions to prevent and control health-care-associated infections: a systematic review. The Lancet Infectious Diseases 2023, 23(7), e228-e239.